ArticleClinical trials (London, England)2020

Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials.

Behnood Bikdeli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.